Objective Clinically, the ankle-brachial blood pressure index (ABI) and skin perfusion pressure (SPP) are used to screen for subclinical peripheral artery disease. However, the association between the SPP and mortality in hemodialysis patients has not been previously reported. We investigated these factors and compared the ABI and SPP in patients receiving hemodialysis. Methods A total of 102 patients receiving maintenance hemodialysis were enrolled in this study. The ABI was determined using an ABI-form (Colin, Japan). The SPP was measured using a SensiLase TM PAD3000 (Kaneka, Osaka, Japan). Results The mean follow-up period was 3.2±1.4 years. A multivariate Cox analysis identified a low ABI (p=0.019) and a low SPP (p=0.047) as being independent predictors of mortality. A receiver operating characteristic (ROC) analysis of the ABI revealed a cutoff point of 1.1 and an area under the curve (AUC) of 0.79, with a sensitivity of 90% and a specificity of 62%. A ROC analysis of the SPP revealed a cutoff point of 54.0 mmHg and an AUC of 0.71, with a sensitivity of 55% and a specificity of 84%. Conclusion Both low ABI and SPP values were found to be independent risk factors for mortality among hemodialysis patients. The cutoff point for ABI as a predictor of mortality was 1.1, while that for SPP was 54.0 mmHg.
Introduction
Peripheral artery disease (PAD) is a common complication in hemodialysis patients. Epidemiological and clinical studies of the general population have demonstrated that the presence of PAD is associated with an increased risk of myocardial infarction and stroke (1, 2) . Recent reports have also suggested that PAD is prevalent among hemodialysis patients (3, 4) and is associated with a poor outcome (4) (5) (6) (7) . Clinically, the ankle-brachial blood pressure index (ABI) is widely used to screen for subclinical PAD and believed to be highly correlated with PAD of the lower extremities (8) . A recent study revealed that the ABI is an independent and potential predictor of all-cause mortality in hemodialysis patients (5) . We also reported that, after a relatively long-term observation period (a maximum of 8.8 years), a multivariate analysis indicated that a low ABI acts independently of other risk factors (6) . The assessment of the skin perfusion pressure (SPP) is also noninvasive and measures the pressure in the limbs without being affected by medial calcific sclerosis, which is widely observed in hemodialysis patients. In contrast, the ABI is affected by medial calcific sclerosis. Almost no reports have examined the association between the SPP and mortality in hemodialysis patients. In the present study, we investigated these factors and compared the ABI and SPP in patients receiving hemodialysis. 
Materials and Methods
A total of 102 consecutive patients receiving maintenance hemodialysis who successfully underwent ABI and SPP examinations at approximately the same time between 2007 and 2010 were retrospectively enrolled in this study. Clinical data were collected, including age, gender, duration of hemodialysis therapy, presence of diabetes mellitus and complications of hypertension. The clinical end point was death from any cause.
The ABI was determined in all patients using an ABIform (Colin, Japan), which simultaneously measures the bilateral arm and ankle blood pressures (brachial and posterior tibial arteries, respectively) according to an oscillometric method. The blood pressure was measured after the patients had rested in a supine position for at least five minutes. The ABI was calculated using the ratio of the ankle systolic pressure to the arm systolic pressure. The systolic pressure of the arm without dialysis access and the lower value of the ankle pressure were used for the calculation. To measure the SPP, a SensiLase TM PAD3000 (Kaneka, Osaka, Japan) was used according to the method described by Castronuovo et al. (9) . Briefly, the SPP was measured with the patient in the supine position at room temperature with a laser Doppler probe enclosed within the bladder of the cuff (a laser pressure transducer cuff), which was wrapped around the patient's foot. The ABI (or SPP) was presented as the ABI (or SPP) of the lower side of the legs.
All data are expressed as the mean ± S.D. Student's t-test was used for comparisons between continuous variables.
Univariate and multivariate Cox proportional hazards models were used to identify predictors of overall survival. A receiver operating characteristic (ROC) analysis was performed to assess the cutoff point, area under the curve (AUC), sensitivity and specificity. All statistical calculations were performed using the JMP 5.1 software program. p values of less than 0.05 were considered to denote statistical significance.
Results
The mean follow-up period was 3.2±1.4 years. The patients' background characteristics are shown in Table 1 . The mean age was 59.3±14.2 years, and the mean duration of hemodialysis therapy was 17.0±14.0 years. The results of the biochemistry tests and the primary causes of end-stage kidney disease are also shown in Table 1 . Hypertension and diabetes mellitus were observed in 60.8% and 20.6% of the study participants, respectively.
During the follow-up period, 20 deaths were recorded. Table 2 shows a Cox proportional hazards analysis of the covariates for predicting mortality. In the univariate analysis, the predictive variables for mortality included an older age, a low serum creatinine level, a low ABI and a low SPP (p= 0.003, p=0.001, p<0.001 and p=0.004, respectively). A multivariate Cox analysis (with age, creatinine, phosphate, calcium phosphate product [Ca × P], diabetes mellitus and ABI as risk factors) identified a low serum phosphate level and a low ABI level as being independent predictors of mortality (p=0.032 and p=0.003, respectively, Table 3a ). A multivariate Cox analysis (with age, phosphate, Ca × P, creatinine, diabetes mellitus and SPP as risk factors) identified a low SPP as an independent predictor of mortality (p=0.047, Table 3b). cutoff point of 1.1 and an AUC of 0.79, with a sensitivity of 90% and specificity of 62% (Figure a) . The ROC analysis of SPP revealed a cutoff point of 54.0 mmHg and an AUC of 0.71, with a sensitivity of 55% and a specificity of 84% (Figure b) . The ROC analysis of the creatinine level revealed an AUC of 0.73, with a sensitivity of 80% and a specificity of 63%, while the ROC analysis of the phosphate level revealed an AUC of 0.58, with a sensitivity of 55% and a specificity of 68%. The ROC analysis of Ca × P revealed an AUC of 0.57, with a sensitivity of 60% and a specificity of 62%.
Discussion
Our results revealed that both low ABI and SPP values are independent risk factors for mortality among hemodialysis patients. In the ROC analyses of predictors of mortality (3.2±1.4-year observation period), the cutoff point for ABI was 1.1, with a sensitivity of 90% and a specificity of 62%, whereas that for SPP was 54.0 mmHg, with a sensitivity of 55% and a specificity of 84%. The AUC was 0.79 for ABI and 0.71 for SPP, which were very similar.
PAD is a common complication in hemodialysis patients, with a reported prevalence of 23.0% in the Hemo study (10) . We previously also demonstrated a high prevalence (22.1%) of PAD among hemodialysis patients (6) . Cardiovascular disease is the leading cause of death in both chronic kidney disease and peritoneal dialysis/hemodialysis patients (2) . PAD is recognized to be a polyvascular disease due to the high correlation between coronary artery disease and cerebrovascular atherosclerosis (11) . An important issue in the management of patients with PAD is the elevated risk of cardiovascular disease, stroke and premature death (12) . Moreover, we recently showed, in a series of 117 hemodialysis patients, that infection was significantly more prevalent in the PAD group than in the non-PAD group (13) . Among the six PAD patients whose cause of death was infection, the foci of infection included lower extremity gangrene in only two patients (13) . The serum albumin and creatinine levels were lower, the serum C-reactive protein levels were higher and the hemoglobin levels were lower in the PAD group than in the non-PAD group (13) . Many patients with malnutrition inflammation atherosclerosis (MIA) syndrome may have also been included in the PAD group. Immune insufficiency, which accompanies MIA syndrome, can lead to infection, thereby resulting in death in PAD patients.
Poor outcomes of hemodialysis patients with PAD have been reported in both short-and long-term observations (5, 6). Ono et al. examined the ABI and mortality in 1,010 hemodialysis patients and found that, while diabetes mellitus was a predictor in a univariate analysis, no statistical significance was observed in a multivariate analysis of all-cause mortality (6) . The authors reported that the impact of diabetes mellitus may be mediated by atherosclerotic vascular disease, as represented by a low ABI (6). Our results appear to be in accordance with their findings. A low serum phosphate level was another risk factor for mortality in the ABI model in the present study. A low serum phosphate level can represent malnutrition, which leads to a poor outcome. The ROC analysis demonstrated a higher accuracy for both ABI and SPP than phosphate or Ca × P. The impact of a high level of phosphate or Ca × P may be mediated by atherosclerotic vascular disease, as represented by a low ABI or SPP.
The ABI is a simple, reliable diagnostic tool that can be used to define the existence and severity of PAD. In the present study, the ABI was determined using the ABI-form (Colin, Japan), which simultaneously measures the arm and ankle blood pressures according to an oscillometric method. This automatic device allowed us to measure the ABI quickly, noninvasively and reproducibly. The SPP is another noninvasive measurement that reflects the local pressure in the microcirculation. The probe is positioned underneath a pressure cuff and the return of flow is detected using laser Doppler velocimetry. The value obtained reflects the blood perfusion in the entire microcirculation, including the arterioles and capillaries (9) . In hemodialysis patients, arteriosclerosis (especially medial calcific sclerosis) is highly prominent. The SPP measures the pressure in the limbs and is not affected by medial calcific sclerosis, which can cause spurious elevations in the segmental systolic pressure measurements. The SPP can also detect the flow in smaller arteries than the ABI. Another factor that may contribute to the diagnostic accuracy of the SPP with respect to PAD is the fact that the measurement can be obtained at the level of the limb or foot, where ulcers or amputation wounds are often located. In patients with involuntary movements, however, the SPP cannot be estimated. Our study also showed that low ABI and SPP values are independent risk factors for mortality among hemodialysis patients. Both the ABI and SPP are simple, reliable diagnostic tools that can be used to define the existence and severity of PAD. Therefore, ABI and SPP measurements can be used to identify high-risk hemodialysis patients requiring intensive follow-up care. A previous report showed that when the cutoff values are set at 0.9 for the ABI and 50 mmHg for the SPP, the SPP is the more useful tool for detecting PAD below the knee using multidetector-row computed tomography in hemodialysis patients [ABI sensitivity, 29.9%; ABI specificity, 100%; SPP sensitivity, 84.9%; SPP specificity, 76.9% (14) . In dialysis patients, both atherosclerosis (primarily affecting the intima of the arteries) and arteriosclerosis (predominantly affecting the media of large-and middle-sized arteries diffusely) are highly prominent. Arteriosclerosis, which is characterized by reduced arterial compliance (i.e., reduced elasticity of the arteries), is caused by increased fibrosis, loss of elastic fibers and extensive vessel wall calcification (15) ]. The transformation of vascular smooth muscle cells into chondrocytes or osteoblast-like cells appears to be a key element in the pathogenesis of vascular calcification, in the context of passive calcium and phosphate deposition resulting from abnormal bone metabolism and impaired renal excretion (16) . Due to the high prevalence of stenosis at more distal locations associated with arterial calcification, the systolic blood pressure measured with a cuff gives a reading higher than the actual pressure. The measured ABI thus appears to be higher than the actual value in hemodialysis patients. The actual cutoff point for hemodialysis patients was higher than 0.9, which is applied as the cutoff point in patients with a normal kidney function. Our study demonstrated that the cutoff point for ABI as a predictor of mortality (3.2±1.4-year observation period) is 1.1, which is higher than the cutoff point for PAD in the normal population. Some at-risk hemodialysis patients may be missed if the ABI is estimated as being normal at a value above 0.9. In this study, the cutoff point for SPP as a predictor of mortality was 54.0 mmHg. This value is similar to the previous cutoff point used for PAD below the knee [50 mmHg (14) ]. Regarding ABI, the specificity was rather low (62%); therefore, caution is needed to ensure that patients with a good prognosis are not misdiagnosed as high-risk patients. With respect to SPP, the sensitivity was also rather low (55%); therefore, caution is required to ensure that high-risk patients are not misdiagnosed as normal.
Our study is associated with several limitations. First, the study was a retrospective examination of patients evaluated at a single institution, and there were differences in care, including medications, over the course of the observation period. In addition, patients in whom neither the ABI nor SPP were measured were not included in this study. Finally, the prevalence of diabetes mellitus was rather low due to the specificity of our institution.
Conclusion
Both low ABI and SPP values are independent risk factors for mortality among hemodialysis patients. In this study, the cutoff point for ABI as a predictor of mortality (3.2±1.4-year observation period) was 1.1, while that for SPP was 54.0 mmHg.
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